| 102036-1 |
Prion protein.abnormal |
Imp |
CSF |
Pt |
Doc |
RT-QuIC |
|
ACTIVE |
Abnormal Prion Protein [Interpretation] in Cerebral spinal fluid Document by RT-QuIC |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
102036-1 |
|
RT-QuIC |
|
|
Both |
|
|
|
0 |
Abn Prion Prot CSF Doc RT-QuIC-Imp |
|
|
|
N |
|
abn; Abn Prion Prot; abnorm; Bovine spongiform encephalopathy; BSE; Cerebral spinal fluid; Cerebrospinal Fl; Document; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Microbiology; Point in time; PR; Prot; PrP; Random; Scrapie; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 102038-7 |
ROS1 gene targeted mutation analysis |
Prid |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
ROS proto-oncogene 1 mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.REARRANGE |
|
102038-7 |
|
Molgen |
|
|
Both |
|
|
|
0 |
ROS1 gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; c-ros-1; Identity or presence; MCF3; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.REARRANGEMENTS; Mut; Mut Anl; Mutations; Nominal; PCR; Point in time; Random; receptor tyrosine kinase; ROS; ROS 1; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.77 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 102039-5 |
MET gene amplification |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
MET gene amplification in Blood or Tissue by Molgen |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
102039-5 |
|
Molgen |
|
|
Both |
|
|
|
0 |
MET gene amplification Bld/T Molgen |
|
|
|
N |
|
AUTS9; Blood; DFNB97; Document; Finding; Findings; HGFR; MET amp; MET proto-oncogene, receptor tyrosine kinase; Molecular genetics; Molecular pathology; MOLPATH; PCR; Point in time; Random; RCCP2; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 10204-6 |
Physical findings |
Find |
Pelvis |
Pt |
Nar |
Observed |
|
ACTIVE |
Physical findings of Pelvis Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.PX |
|
10204-6 |
|
Observed |
|
|
|
|
|
|
0 |
Phys find Pelvis |
|
|
|
|
|
Exam; Examination; Finding; Findings; H+P; H+P.PX; Narrative; P prime; Pelvic; Phys find; Point in time; Random; Report |
2.4 |
1.0i |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 102040-3 |
Polygenic risk score |
Score |
^Patient |
Lifetime |
Qn |
|
|
ACTIVE |
Polygenic risk score (PRS) |
|
MIN |
DefinitionDescription |
|
|
score |
|
|
|
|
|
|
CLIN.RISK |
|
102040-3 |
|
|
|
|
Observation |
|
|
|
0 |
Polygenic risk score |
|
|
|
N |
|
CLIN; CLIN.RISK; QNT; Quan; Quant; Quantitative; Scale |
2.77 |
2.75 |
|
|
|
|
|
|
|
{score} |
|
|
|
0 |
| 102041-1 |
Carboxy tetrahydrocannabinol Delta 9/Creatinine |
MRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Carboxy tetrahydrocannabinol Delta 9/Creatinine [Mass Ratio] in Urine |
|
MAJ |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
102041-1 |
|
|
|
|
Both |
|
|
|
0 |
THC-9-COOH/Creat Ur |
|
|
|
N |
|
11-nor-9-carboxy-delta-9-THC; 11-nor-9-carboxy-THC; 11-nor-delta-9-THC-9-COOH; 9-carboxy-11-nor-delta-9-tetrahydrocannabinol; 9-Carboxy-delta(9)-thc; 9-Carboxy-thc; C22H30O4; Carboxytetrahydrocannabinol; CarboxyTHC; Carboxy-THC-delta-9; CR; Crea; Creat; delta(9)-Tetrahydrocannabinolic acid; Delta(9)-THC; Delta-9-tetrahydrocannabinol; Delta-9-tetrahydrocannabinol metabolite; Dronabinol; DRUG/TOXICOLOGY; Drugs; Marijuana; Mass concentration ratio; Mass ratio; MCRto; Nabilone; Point in time; QNT; Quan; Quant; Quantitative; Random; THC; THC-9-COOH; THC-9-COOH/Cr; THCA; THCA-A; THCC; THCCOOH; THC-COOH; UA; UCr; UR; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 102042-9 |
Lung cancer panel |
- |
Lung tiss |
Pt |
- |
Sequencing |
|
ACTIVE |
Lung cancer panel |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MOLPATH |
|
102042-9 |
|
Sequencing |
|
|
Order |
|
|
|
0 |
CA, lung tiss, panel |
|
|
|
N |
|
high-throughput sequencing; HTS; Lung CA panel; Molecular pathology; MOLPATH; Next generation sequencing; NGS; Pan; Panel.molpath; Panl; Pnl; Point in time; Pulmonary; Random; Tissue; Tissue lung; Tissue, unspecified; Tlng |
2.76 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 102043-7 |
Synoptic report |
Find |
Lung |
Pt |
Nar |
Surgical oncology |
|
ACTIVE |
Surgical oncology of lung cancer synoptic report |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURG |
|
102043-7 |
|
Surgical oncology |
|
|
Both |
|
|
|
0 |
Surg onc lung CA synoptic rpt |
|
|
|
N |
|
Cancer; Finding; Findings; General surgical oncology; Narrative; Point in time; Pulmonary; Random; Report; Surg; Surg Onc |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 102044-5 |
Synoptic report |
Find |
Stomach |
Pt |
Nar |
Surgical oncology |
|
ACTIVE |
Surgical oncology of stomach cancer synoptic report |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURG |
|
102044-5 |
|
Surgical oncology |
|
|
Both |
|
|
|
0 |
Surg onc stomach CA synoptic rep |
|
|
|
N |
|
Cancer; Finding; Findings; General surgical oncology; Narrative; Point in time; Random; Report; Surg; Surg Onc |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 102045-2 |
Synoptic report |
Find |
Adrenal gland |
Pt |
Nar |
Surgical oncology |
|
ACTIVE |
Synoptic report for adrenal gland cancer surgery |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURG |
|
102045-2 |
|
Surgical oncology |
|
|
Both |
|
|
|
0 |
Surg onc adrenal gland CA synoptic rept |
|
|
|
N |
|
Cancer; Finding; Findings; General surgical oncology; Narrative; Point in time; Random; Report; Surg; Surg Onc |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 102046-0 |
Synoptic report |
Find |
Tiss |
Pt |
Nar |
Surgical oncology |
|
ACTIVE |
Surgical oncology of sarcoma cancer synoptic report |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURG |
|
102046-0 |
|
Surgical oncology |
|
|
Both |
|
|
|
0 |
Surg onc sarc CA synoptic rep |
|
|
|
N |
|
Cancer; Finding; Findings; General surgical oncology; Narrative; Point in time; Random; Report; Surg; Surg Onc; Tissue; Tissue, unspecified |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 102047-8 |
Synoptic report |
Find |
Rectum |
Pt |
Nar |
Surgical oncology |
|
ACTIVE |
Surgical oncology of rectum cancer synoptic report |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURG |
|
102047-8 |
|
Surgical oncology |
|
|
Both |
|
|
|
0 |
Surg onc rectum CA synoptic rep |
|
|
|
N |
|
Cancer; Finding; Findings; General surgical oncology; Narrative; Point in time; Random; Rectal; Report; Surg; Surg Onc |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 102048-6 |
SARS coronavirus 2 & Respiratory syncytial virus Ag |
PrThr |
Nasopharynx |
Pt |
Ord |
IF |
|
ACTIVE |
SARS coronavirus 2 and Respiratory syncytial virus Ag [Presence] in Nasopharynx by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
102048-6 |
|
IF |
|
|
Both |
|
|
|
0 |
SARS (COVID-2) + RSV Ag Nasoph Ql IF |
|
|
|
N |
|
2019 Novel Coronavirus; 2019-nCoV; ACIF; Anticomplement Immunofluorescence; Antigen; Antigens; Corona virus; COVID19; COVID-19; DFA; FA; Fluorescent antibody; Fluoresent; HRSV; IFA; II; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; RSV; SARS (COVID-2) + RSV; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; SARS-CoV-2 + RSV; Screen; Severe Acute Respiratory Syndrome; Time Resolved Fluorescence; TRF; Viral Pneumonias; Wuhan coronavirus |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 102049-4 |
Hereditary sensory + autonomic neuropathy type 1 panel |
- |
Ser |
Pt |
- |
LC/MS/MS |
|
ACTIVE |
Hereditary sensory and autonomic neuropathy type 1 panel - Serum by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
102049-4 |
|
LC/MS/MS |
|
|
Order |
|
|
|
0 |
HSAN1 panel Ser LC/MS/MS |
|
|
|
N |
|
Chemistry; HSAN1; HSAN1 panel; HSN1; i; Pan; PANEL.CHEMISTRY; Panl; Pnl; Point in time; Random; Serum; SR |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 10205-3 |
Physical findings |
Find |
Rectum |
Pt |
Nar |
Observed |
|
ACTIVE |
Physical findings of Rectum Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.PX |
|
10205-3 |
|
Observed |
|
|
|
|
|
|
0 |
Phys find Rectum |
|
|
|
|
|
Exam; Examination; Finding; Findings; H+P; H+P.PX; Narrative; P prime; Phys find; Point in time; Random; Rectal; Report |
2.73 |
1.0i |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 102050-2 |
Diabetic diagnosis |
Prid |
^Patient |
Pt |
Nom |
|
|
ACTIVE |
Diabetic diagnosis [Identifier] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MISC |
|
102050-2 |
|
|
|
|
Observation |
|
|
|
0 |
Diabetic Dx Patient |
|
|
|
N |
|
Diabetic Dx; Dx; Identity or presence; MISC; Nominal; Point in time; Random |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 102051-0 |
1-deoxysphinganine |
MCnc |
Ser |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
1-deoxysphinganine [Mass/volume] in Serum by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
Reference value <=0.25 |
|
|
|
CHEM |
|
102051-0 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
1-deoxySa Ser LC/MS/MS-mCnc |
|
|
|
N |
|
1-deoxySa; 1-deoxysphinganinium; Chemistry; i; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 102052-8 |
(2S,3R)-2-Amino-4-octadecene-3-ol |
MCnc |
Ser |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
1-Deoxysphingosine [Mass/volume] in Serum by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
Reference value <=0.05 |
|
|
|
CHEM |
|
102052-8 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
1-Deoxysphingosine Ser LC/MS/MS-mCnc |
|
|
|
N |
|
1-Deoxysphingosine; C18H37NO; Chemistry; deoxysphingosine; II; III; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 102053-6 |
1-deoxymethylsphinganine |
MCnc |
Ser |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
1-deoxymethylsphinganine [Mass/volume] in Serum by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
Reference value <=0.04 |
|
|
|
CHEM |
|
102053-6 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
1-DOXCH3sphinganine Ser LC/MS/MS-mCnc |
|
|
|
N |
|
(2R)-1-aminoheptadecan-2-ol; 1-DOXCH3sphinganine; Chemistry; deoxymethyl-SA; i; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 102054-4 |
1-deoxymethylsphingosine |
MCnc |
Ser |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
1-deoxymethylsphingosine [Mass/volume] in Serum by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
Reference value <=0.09 |
|
|
|
CHEM |
|
102054-4 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
1-DOXCH3sphingosine Ser LC/MS/MS-mCnc |
|
|
|
N |
|
1-DOXCH3sphingosine; Chemistry; i; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 102055-1 |
Sphinganine |
MCnc |
Ser |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Sphinganine [Mass/volume] in Serum by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
Reference value <=18.00 |
|
|
|
CHEM |
|
102055-1 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
Sphinganine Ser LC/MS/MS-mCnc |
|
|
|
N |
|
Chemistry; D-erythro-Sphinganine; Dihydrosphingosine; Level; Mass concentration; Octadecasphinganine; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 102056-9 |
Sphingosine |
MCnc |
Ser |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Sphingosine [Mass/volume] in Serum by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
Reference value <=80.00 |
|
|
|
CHEM |
|
102056-9 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
Sphingosine Ser LC/MS/MS-mCnc |
|
|
|
N |
|
123-78-4; Chemistry; D-erythro-Sphingosine; D-Sphingosine; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 102057-7 |
Sphingolipid panel |
- |
Ser |
Pt |
- |
|
|
ACTIVE |
Sphingolipid panel - Serum |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
102057-7 |
|
|
|
|
Order |
|
|
|
0 |
Sphingolipid pnl Ser |
|
|
|
N |
|
Chemistry; Pan; PANEL.CHEMISTRY; Panl; Pnl; Point in time; Random; Serum; Sphingolipid pnl; SR |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 102058-5 |
Perfluorohexanoate |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Perfluorohexanoate [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102058-5 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
PFHxA SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; PFHxA; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Undecafluorohexanoic acid |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: updated to the anionic name; |
0 |
| 102059-3 |
Perfluorobutane Sulfonic Acid |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Perfluorobutane Sulfonic Acid [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102059-3 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
PFBS SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
Acd; Acids; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Nonafluoro-1-butanesulfonic acid; Nonafluorobutane-1-sulfonic acid; Nonafluorobutanesulfonic acid; PFBS; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
